Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

The Effects of Drug Metabolizing Enzyme Inhibitors on Hepatic Efflux and Uptake Transporters.

Cheong J, Halladay JS, Plise E, Sodhi JK, Salphati L.

Drug Metab Lett. 2017;11(2):111-118. doi: 10.2174/1872312811666171010101248.

PMID:
29032766
2.

Inhibitory Effects of Trapping Agents of Sulfur Drug Reactive Intermediates against Major Human Cytochrome P450 Isoforms.

Sodhi JK, Delarosa EM, Halladay JS, Driscoll JP, Mulder T, Dansette PM, Khojasteh SC.

Int J Mol Sci. 2017 Jul 20;18(7). pii: E1553. doi: 10.3390/ijms18071553.

3.

Novel Mechanism of Decyanation of GDC-0425 by Cytochrome P450.

Takahashi RH, Halladay JS, Siu M, Chen Y, Hop CE, Khojasteh SC, Ma S.

Drug Metab Dispos. 2017 May;45(5):430-440. doi: 10.1124/dmd.116.074336. Epub 2017 Feb 10.

PMID:
28188299
4.

Going Beyond Common Drug Metabolizing Enzymes: Case Studies of Biotransformation Involving Aldehyde Oxidase, γ-Glutamyl Transpeptidase, Cathepsin B, Flavin-Containing Monooxygenase, and ADP-Ribosyltransferase.

Fan PW, Zhang D, Halladay JS, Driscoll JP, Khojasteh SC.

Drug Metab Dispos. 2016 Aug;44(8):1253-61. doi: 10.1124/dmd.116.070169. Epub 2016 Apr 26. Review.

PMID:
27117704
5.

A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834.

Sodhi JK, Wong S, Kirkpatrick DS, Liu L, Khojasteh SC, Hop CE, Barr JT, Jones JP, Halladay JS.

Drug Metab Dispos. 2015 Jun;43(6):908-15. doi: 10.1124/dmd.114.061804. Epub 2015 Apr 6.

6.

1-Aminobenzotriazole coincubated with (S)-warfarin results in potent inactivation of CYP2C9.

Sodhi JK, Ford KA, Mukadam S, Wong S, Hop CE, Khojasteh SC, Halladay JS.

Drug Metab Dispos. 2014 May;42(5):813-7. doi: 10.1124/dmd.113.055913. Epub 2014 Feb 18.

PMID:
24550229
7.

On the maintenance of hepatocyte intracellular pH 7.0 in the in-vitro metabolic stability assay.

Berezhkovskiy LM, Wong S, Halladay JS.

J Pharmacokinet Pharmacodyn. 2013 Dec;40(6):683-9. doi: 10.1007/s10928-013-9339-8. Epub 2013 Nov 1.

PMID:
24178037
8.

Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist.

Wong H, Gould SE, Budha N, Darbonne WC, Kadel EE 3rd, La H, Alicke B, Halladay JS, Erickson R, Portera C, Tolcher AW, Infante JR, Mamounas M, Flygare JA, Hop CE, Fairbrother WJ.

Drug Metab Dispos. 2013 Dec;41(12):2104-13. doi: 10.1124/dmd.113.053926. Epub 2013 Sep 16.

PMID:
24041744
9.

Comparative assessment of In Vitro-In Vivo extrapolation methods used for predicting hepatic metabolic clearance of drugs.

Poulin P, Hop CE, Ho Q, Halladay JS, Haddad S, Kenny JR.

J Pharm Sci. 2012 Nov;101(11):4308-26. doi: 10.1002/jps.23288. Epub 2012 Aug 13.

PMID:
22890957
10.

An 'all-inclusive' 96-well cytochrome P450 induction method: measuring enzyme activity, mRNA levels, protein levels, and cytotoxicity from one well using cryopreserved human hepatocytes.

Halladay JS, Wong S, Khojasteh SC, Grepper S.

J Pharmacol Toxicol Methods. 2012 Nov-Dec;66(3):270-5. doi: 10.1016/j.vascn.2012.07.004. Epub 2012 Jul 15.

PMID:
22809809
11.

Evaluation of time-dependent cytochrome p450 inhibition in a high-throughput, automated assay: introducing a novel area under the curve shift approach.

Mukadam S, Tay S, Tran D, Wang L, Delarosa EM, Khojasteh SC, Halladay JS, Kenny JR.

Drug Metab Lett. 2012 Mar;6(1):43-53.

PMID:
22372554
12.
13.

Novel mechanism for dehalogenation and glutathione conjugation of dihalogenated anilines in human liver microsomes: evidence for ipso glutathione addition.

Zhang C, Kenny JR, Le H, Deese A, Ford KA, Lightning LK, Fan PW, Driscoll JP, Halladay JS, Hop CE, Khojasteh SC.

Chem Res Toxicol. 2011 Oct 17;24(10):1668-77. doi: 10.1021/tx2002228. Epub 2011 Sep 25.

PMID:
21905702
14.

High-throughput, 384-well, LC-MS/MS CYP inhibition assay using automation, cassette-analysis technique, and streamlined data analysis.

Halladay JS, Delarosa EM, Tran D, Wang L, Wong S, Khojasteh SC.

Drug Metab Lett. 2011 Aug;5(3):220-30.

PMID:
21867481
15.

Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human.

Salphati L, Pang J, Plise EG, Chou B, Halladay JS, Olivero AG, Rudewicz PJ, Tian Q, Wong S, Zhang X.

Xenobiotica. 2011 Dec;41(12):1088-99. doi: 10.3109/00498254.2011.603384. Epub 2011 Aug 13.

PMID:
21838594
16.

High-Throughput, 384-Well, LC-MS/MS CYP Inhibition Assay Using Automation, Cassette-Analysis Technique, and Streamlined Data Analysi.

Halladay JS, Delarosa EM, Tran D, Wang L, Wong S, Khojasteh SC.

Drug Metab Lett. 2011 Aug 9. [Epub ahead of print]

PMID:
21824084
17.

Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor.

Liu L, Halladay JS, Shin Y, Wong S, Coraggio M, La H, Baumgardner M, Le H, Gopaul S, Boggs J, Kuebler P, Davis JC Jr, Liao XC, Lubach JW, Deese A, Sowell CG, Currie KS, Young WB, Khojasteh SC, Hop CE, Wong H.

Drug Metab Dispos. 2011 Oct;39(10):1840-9. doi: 10.1124/dmd.111.040840. Epub 2011 Jul 8.

PMID:
21742900
18.

Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.

Khojasteh SC, Prabhu S, Kenny JR, Halladay JS, Lu AY.

Eur J Drug Metab Pharmacokinet. 2011 Mar;36(1):1-16. doi: 10.1007/s13318-011-0024-2. Epub 2011 Feb 19. Review.

PMID:
21336516
19.

Formation of a quinoneimine intermediate of 4-fluoro-N-methylaniline by FMO1: carbon oxidation plus defluorination.

Driscoll JP, Aliagas I, Harris JJ, Halladay JS, Khatib-Shahidi S, Deese A, Segraves N, Khojasteh-Bakht SC.

Chem Res Toxicol. 2010 May 17;23(5):861-3. doi: 10.1021/tx1000688.

PMID:
20369854
20.

Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.

Wong H, Chen JZ, Chou B, Halladay JS, Kenny JR, La H, Marsters JC Jr, Plise E, Rudewicz PJ, Robarge K, Shin Y, Wong S, Zhang C, Khojasteh SC.

Xenobiotica. 2009 Nov;39(11):850-61. doi: 10.3109/00498250903180289.

PMID:
19845436
21.

Inhibitory properties of trapping agents: glutathione, potassium cyanide, and methoxylamine, against major human cytochrome p450 isoforms.

Zhang C, Wong S, Delarosa EM, Kenny JR, Halladay JS, Hop CE, Khojasteh-Bakht SC.

Drug Metab Lett. 2009 Apr;3(2):125-9.

PMID:
19601875
22.

On the prediction of hepatic clearance using the diluted plasma in metabolic stability assay.

Berezhkovskiy LM, Khojasteh SC, Halladay JS, Hop CE.

J Pharm Sci. 2009 Jun;98(6):1922-7. doi: 10.1002/jps.21582.

PMID:
18837013
23.

Metabolic stability screen for drug discovery using cassette analysis and column switching.

Halladay JS, Wong S, Jaffer SM, Sinhababu AK, Khojasteh-Bakht SC.

Drug Metab Lett. 2007 Jan;1(1):67-72.

PMID:
19356021
24.
25.

Metabolism and disposition of [(14)C]1-nitronaphthalene in male Sprague-Dawley rats.

Halladay JS, Sauer JM, Sipes IG.

Drug Metab Dispos. 1999 Dec;27(12):1456-65.

PMID:
10570027

Supplemental Content

Loading ...
Support Center